ArticleAnnals of intensive care2026
Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis.
Article in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the recent years, multiple myeloma (MM) has been associated with long-term survival. Life-threatening complications may occur in those patients leading to high risk of ICU admission. Within the same period, survival of critically ill patients with malignancy improved. The aim of this study was to evaluate severity and outcome in patients with MM admitted to ICU within the last 16 years. Methods: In this monocentric retrospective study, patients with MM admitted to ICU within two periods (2007-2015) and (2016-2023) around major therapeutic changes, were included. Patients from two periods were compared in terms of short and long terms outcomes. In the recent period, factors associated with mortality were assessed by multivariate analysis. Results: During the first period (2007-2015), 199 patients were included and compared to 229 patients admitted within the second period (2016-2023). Median delay from MM diagnosis to ICU was 25.9 (2.2-70.6) months and 82 (19.2%) patients were newly diagnosed patients. MM classified as high risk concerned 119 (52%) or Stade III Salmon-Durie for 142 (71.4 %) patients. SOFA score on Day 1 was 5 (2-7). During ICU stay, 115 (26.9%) patients needed invasive mechanical ventilation, 105 (24.5%) patients received vasopressors and 97 (22.7%) had renal replacement therapy. Median length of ICU stay was 3 (2-6) days. Reason for ICU admission was different between the two periods: Shock was more frequent in the second period (29.7% vs 13.7%) whereas acute respiratory failure was more frequent in the first period (35.2% vs 46.7%) (p < 0.001). ICU and one-year mortality rates were respectively 12.1% (n = 50) and 40.6% (n = 170). Mortality rates, adjusted on age, comorbidities, more than 2 lines treatment, time between hospital and ICU admission >1 day, kidney amyloidosis, SOFA score at ICU admission and reason for ICU admission, were lower in the recent period compared to the first period (0.68 (0.49-0.95), p = 0.02). Conclusions: Survival in MM patients admitted to ICU improved in the recent years. Particularly, patients who were not previously heavily treated had better outcome and should be admitted to ICU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.